| Velcade Side Effect Report | Date Submitted |
|---|---|
| \"ACUTE, CRONIC, SEVERE\" NEUROPATHY (words of neu | 2008-06-01 |
Velcade Side Effect Reports Summary
PatientsVille.com - Empowering Patients
Velcade Studies
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Pati
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple
Open-label Study of TH-302 as Monotherapy and in Combination With Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Bortezomib Consolidation Trial
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With R
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Study to Compare Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Re
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplan
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Bortezomib Plus Rituximab for EBV+ PTLD
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Bortezomib and Romidepsin in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Panobinostat/Velcade in Multiple Myeloma
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies
You took Velcade and now feel unusual symptoms. It could be Velcade side effect. Help Community - Submit Your Side Effect.
Mobile version
How Did You Deal with Side Effects?Velcade Side Effects - Complete Patient's Guide | User Reviews: Female patient, weighting 219.0 lb, was diagnosed with |Dierrhoea, Platelet Count, Weight Loss, Slight ...<<<<
Velcade Side Effects Reported and Ranked by Velcade Users |Dierrhoea, Platelet Count, Weight Loss, Slight Neuropathy, Including<<<<
Post Velcade Side Effect Reporting Your Velcade side effect will help others recognize and deal with Velcade side effects. Recent Reports View Velcade reports ...<<<<
About Velcade : Risks and Benefits, News and Updates, Velcade video and TV resources<<<<
Velcade Side Effects - Complete Patient's Guide | User Reviews: Male patient, 67 years of age, weighting 152.6 | 3|Dierrhoea, Platelet Count, Weight Loss, Slight ...<<<<
Side Effects of Velcade Discussions: Patient comment about their Velcade side effects experience.<<<<
velcade Episodes: 8: Diagnosed with major depression.Side effects: cardiac failure, myocarditis More: viagra Episodes: 3: Diagnosed with major depression.Side ...<<<<
AMYLOIDOSIS, view Drugs and Side Effects associated with AMYLOIDOSIS, ,AMYLOIDOSIS REVLIMID,AMYLOIDOSIS VELCADE,AMYLOIDOSIS REMICADE,AMYLOIDOSIS THALOMID,AMYLOIDOSIS ...<<<<
During the same period patient was treated with VELCADE (Day 1, 4, 8 And 11) (View Velcade Review and Velcade Label ), VINCRISTINE (Day 1,8, 15 And 22) (View Vincristine ...<<<<
During the same period patient was treated with VELCADE (Days 1,4,8,11 Of Cycle) (View Velcade Review and Velcade Label ), DEXAMETHASONE (Days 1-4, 9-12, 17-20 Of Cycle ...<<<<